By Turna Ray

Following the accelerated approval of Vectibix in the US in 2006, follow-on studies have failed to show that metastatic colorectal cancer patients on the drug live longer than those receiving standard chemotherapies. However, Amgen this week said it is in the process of conducting a study to try to prove that Vectibix-treated chemorefractory patients whose tumors express the wild-type KRAS gene do survive longer than patients receiving just chemotherapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.